TrialCancer immunology, immunotherapy : CII2025

The impact of tislelizumab immunotherapy on multiple primary lung cancer presenting as ground-glass nodules: preliminary results analysis from a single-arm, phase II trial.

Junfei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.